[Form 4] Karyopharm Therapeutics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. reported that its President and CEO, Richard A. Paulson, received an award of 81,060 shares of common stock in the form of restricted stock units (RSUs) on February 5, 2026. The RSUs were granted at $0 per share under the company’s 2022 Equity Incentive Plan and increase his directly held beneficial ownership to 279,391 shares of common stock.

The RSUs convert into common stock on a one-for-one basis. Vesting is scheduled so that 50% of the RSUs vest on January 31, 2027, with the remaining 50% vesting on January 31, 2028, tying a portion of the CEO’s compensation to the company’s long-term performance and continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Paulson Richard A.

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	81,060	$0.00	--

Holdings After Transaction: Common Stock — 279,391 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paulson Richard A.

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		A		81,060(1)	A	$0	279,391	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.

	/s/ Nancy Smith as Attorney-in-Fact for Richard Paulson	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Karyopharm (KPTI) report for its CEO?

Karyopharm reported that President and CEO Richard A. Paulson received an award of 81,060 restricted stock units. These RSUs were granted at $0 per share under the 2022 Equity Incentive Plan and will convert into Karyopharm common stock on a one-for-one basis after vesting.

How many Karyopharm (KPTI) shares does the CEO own after this Form 4?

After the reported RSU award, Richard A. Paulson beneficially owns 279,391 shares of Karyopharm common stock directly. This figure includes the impact of the 81,060 restricted stock units granted on February 5, 2026, as disclosed in the Form 4 filing.

What are the vesting terms of the CEO’s RSUs at Karyopharm (KPTI)?

The 81,060 restricted stock units vest in two equal installments. Fifty percent of the RSUs vest on January 31, 2027, and the remaining fifty percent vest on January 31, 2028. Each vested RSU converts into one share of Karyopharm common stock upon settlement.

Under which plan were the RSUs granted to Karyopharm’s CEO?

The restricted stock units awarded to Richard A. Paulson were granted under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. This plan governs equity-based compensation, including RSUs that convert into Karyopharm common stock on a one-for-one basis after vesting.

Was there any cash consideration in the CEO’s Karyopharm (KPTI) RSU grant?

No cash consideration was involved in the RSU grant to the CEO. The Form 4 shows the 81,060 restricted stock units were acquired at a reported price of $0 per share as part of equity compensation under the company’s 2022 Equity Incentive Plan.

What role does Richard A. Paulson hold at Karyopharm (KPTI)?

Richard A. Paulson serves as both President and Chief Executive Officer of Karyopharm Therapeutics Inc. He is also a director of the company. The Form 4 identifies him in these roles while reporting his award of 81,060 restricted stock units.